报价延迟最少15分钟:2025/09/04 05:14 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.32
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.03/-5.15
|
|
企业价值
256.29M
|
| 资产负债 |
|
每股账面净值
9.98
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
210.78M
|
|
每股收益
2.29
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/04 05:14 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion. |
